Bücher zum Thema „Metalloproteinases Inhibitors Therapeutic use“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Bücher für die Forschung zum Thema "Metalloproteinases Inhibitors Therapeutic use" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Bücher für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Rotheim, Philip. New developments in therapeutic enzyme inhibitors and receptor blockers. Norwalk, CT: Business Communications Co., 1996.
Goudot-Perrot, Andrée. Metabolic inhibitors: Antibiotics - antimitotics - psychotropics. Stuttgart: Schwer Verlag, 1992.
Co, Business Communications. New developments in therapeutic enzyme inhibitors and blockers. Norealk, CT: Business Communications Co., 2002.
George, Weinbaum, Giles Ralph E, Krell Robert D, New York Academy of Sciences. und American Thoracic Society, Hrsg. Pulmonary emphysema: The rationale for therapeutic intervention. New York, N.Y: New York Academy of Sciences, 1991.
PhD, Henderson Brian, und Bodmer Mark W, Hrsg. Therapeutic modulation of cytokines. Boca Raton, Fla: CRC Press, 1996.
K, Ghosh Arun. Aspartic acid proteases as therapeutic targets. Weinheim: Wiley-VCH, 2010.
K, Ghosh Arun. Aspartic acid proteases as therapeutic targets. Weinheim: Wiley-VCH, 2010.
Philippe, Taupin, Hrsg. The cystatin superfamily of proteinase inhibitors. New York: Nova Science Publishers, 2007.
Osiadacz, Jarosław. Inhibitory topoizomeraz DNA i ich zastosowanie w chemioterapii. Wrocław: Oficyna Wydawnicza Politechniki Wrocławskiej, 1999.
Li, William W. The antiangiogenic therapy self help book for cancer patients. Cambridge, Mass: Angiogenesis Foundation, 2003.
International FOIPAN Symposium. (1988 Shizuoka, Japan). Therapeutic basis of synthetic protease inhibitor: Proceedings of the International FOIPAN Symposium held as a Satellite of the 7th International Symposium on Gastrointestinal Hormones, November 4, 1988, Shizuoka, Japan. Herausgegeben von Kanno Tomio 1933-, Miyoshi A, Biomedical Research Foundation (Japan) und International Symposium on Gastrointestinal Hormones. (7th : 1988 : Shizuoka, Japan). Tokyo: Biomedical Research Foundation, 1989.
Mantovani, Alberto. Pharmacology of cytokines. Oxford: Oxford University Press, 2000.
N, DeBrue Anne, Hrsg. Angiotensin converting enzyme inhibitors. New York: Nova Biomedical Books, 2009.
Lane, I. William. Comprehensive research papers on the therapeutic use of shark cartilage. Kerrville, TX: Information Services, 1992.
Chiba, Tsutomu, P. Malfertheiner und Hiroshi Satoh. Proton pump inhibitors: A balanced view. Basel: Karger, 2013.
Strube, Gillian. ACE inhibitors in hypertension: A guide for general practitioners. Dordrecht: Kluwer Academic Publishers, 1992.
Shiau, Judy Y. The efficacy of proton pump inhibitors in adults with functional dyspepsia. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2002.
H, Opie Lionel. Angiotensin-converting enzyme inhibitors: Scientific basis for clinical use. New York: Wiley-Liss, 1992.
Ezio, Giacobini, und Becker Robert E, Hrsg. Current research in Alzheimer therapy: Cholinesterase inhibitors. New York: Taylor & Francis, 1988.
Chang, Henry E. HIV protease inhibitor report. 2. Aufl. Brooklyn, NY (72 Orange St., #3C, Brooklyn 11201): National AIDS Treatment Advocacy Project, 1996.
National Institute for Clinical Excellence (Great Britain). Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence, 2001.
Donnelly, Raymond P. Cytokine therapies: Novel approaches for clinical indications. Boston, Mass: Blackwell Pub. on behalf of the New York Academy of Sciences, 2009.
Krul, Kenneth G. Transcription inhibitors: The next generation of therapeutics. Waltham, Mass: Decision Resources, Inc., 1996.
H, Opie Lionel. Angiotensin-converting enzyme inhibitors: Scientific basis for clinical use. New York: Wiley-Liss, 1992.
K, Ferguson Roger, und Vlasses Peter, Hrsg. Angiotensin-converting enzyme inhibitors. Mount Kisco, N.Y: Futura Pub. Co., 1987.
1943-, Greenwald Robert A., Golub Lorne M und New York Academy of Sciences., Hrsg. Inhibition of matrix metalloproteinases: Therapeutic potential. New York, N.Y: New York Academy of Sciences, 1994.
Clendeninn, Neil J., und Krzysztof Appelt. Matrix Metalloproteinase Inhibitors in Cancer Therapy. Humana Press, 2000.
(Editor), Robert A. Greenwald, New York Academy of Sciences (Corporate Author) und Lorne M. Golub (Editor), Hrsg. Inhibition of Matrix Metalloproteinases: Therapeutic Potential (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1994.
(Editor), Robert A. Greenwald, Stanley Zucker (Editor) und Lorne M. Golub (Editor), Hrsg. Inhibition of Matrix Metalloproteinases: Therapeutic Applications (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1999.
Kevin M.K. Bottomley (Editor), David Bradshaw (Editor) und John S. Nixon (Editor), Hrsg. Metalloproteinases as Targets for Anti-Inflammatory Drugs (Progress in Inflammation Research). Birkhäuser Basel, 1999.
(Editor), Robert A. Greenwald, New York Academy of Sciences (Corporate Author) und Lorne M. Golub (Editor), Hrsg. Inhibition of Matrix Metalloproteinases: Therapeutic Potential (Annals of the New York Academy of Sciences, Vol 732). New York Academy of Sciences, 1994.
(Editor), Neil J. Clendeninn, und Krzysztof Appelt (Editor), Hrsg. Matrix Metalloproteinase Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development). Humana Press, 2001.
Therapeutic Kinase Inhibitors. Springer, 2012.
Page, Clive, Christian Schudt, Gordon Dent und Klaus F. Rabe. Phosphodiesterase Inhibitors. Elsevier Science & Technology Books, 1996.
1957-, D'Orléans-Juste P., und Plante G. E, Hrsg. ACE inhibitors. Basel: Birkhäuser Verlag, 2001.
Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents (Crc Enzyme Inhibitors). CRC, 2006.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2021.
Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.
Weinbaum, George, Ralph E. Giles und Robert D. Krell. Pulmonary emphysema : The rationale for therapeutic intervention. New York Academy of Sciences, 1991.
Machajewski, Timothy D., Zhenhai Gao, Brian Blagg, Tim Haystead und Len Neckers. Inhibitors of Molecular Chaperones As Therapeutic Agents. Royal Society of Chemistry, The, 2013.
Picard, Didier, Timothy D. Machajewski, Zhenhai Gao, David P. Rotella und Chrisostomos Prodromou. Inhibitors of Molecular Chaperones As Therapeutic Agents. Royal Society of Chemistry, The, 2013.
Aromatase inhibitors. Basel: Birkhäuser, 2006.
Brodie, Angela, J. Michael Dixon, Robert Paridaens, Miller William R und B. J. A. Furr. Aromatase Inhibitors. Springer London, Limited, 2006.
Brodie, Angela, Aman Buzdar, Per Eystein Lonning, J. Michael Dixon und B. J. A. Furr. Aromatase Inhibitors. Birkhauser Verlag, 2008.
Mousa, Shaker A. Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications. Taylor & Francis Group, 2000.
Zhang, Jie. PARP as a Therapeutic Target (Handbooks in Pharmacology and Toxicology). CRC, 2002.